Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 1:342:d738.
doi: 10.1136/bmj.d738.

Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study

Rebecca Kuepper  1 , Jim van Os, Roselind Lieb, Hans-Ulrich Wittchen, Michael Höfler, Cécile Henquet
Affiliations

Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study

Rebecca Kuepper et al. BMJ. .

Abstract

Objective: To determine whether use of cannabis in adolescence increases the risk for psychotic outcomes by affecting the incidence and persistence of subclinical expression of psychosis in the general population (that is, expression of psychosis below the level required for a clinical diagnosis).

Design: Analysis of data from a prospective population based cohort study in Germany (early developmental stages of psychopathology study).

Setting: Population based cohort study in Germany.

Participants: 1923 individuals from the general population, aged 14-24 at baseline.

Main outcome measure: Incidence and persistence of subthreshold psychotic symptoms after use of cannabis in adolescence. Cannabis use and psychotic symptoms were assessed at three time points (baseline, T2 (3.5 years), T3 (8.4 years)) over a 10 year follow-up period with the Munich version of the composite international diagnostic interview (M-CIDI).

Results: In individuals who had no reported lifetime psychotic symptoms and no reported lifetime cannabis use at baseline, incident cannabis use over the period from baseline to T2 increased the risk of later incident psychotic symptoms over the period from T2 to T3 (adjusted odds ratio 1.9, 95% confidence interval 1.1 to 3.1; P=0.021). Furthermore, continued use of cannabis increased the risk of persistent psychotic symptoms over the period from T2 to T3 (2.2, 1.2 to 4.2; P=0.016). The incidence rate of psychotic symptoms over the period from baseline to T2 was 31% (152) in exposed individuals versus 20% (284) in non-exposed individuals; over the period from T2 to T3 these rates were 14% (108) and 8% (49), respectively.

Conclusion: Cannabis use is a risk factor for the development of incident psychotic symptoms. Continued cannabis use might increase the risk for psychotic disorder by impacting on the persistence of symptoms.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Study design. Top: testing association between incident cannabis use with onset in period from baseline to T2 and incident psychotic symptoms with onset in period from T2 to T3 in individuals who had not used cannabis at baseline and who had not reported any psychotic experience at T2 (that is, no lifetime psychotic experiences by T2). Bottom: testing association between different cannabis exposure states (combinations of cannabis use at baseline (lifetime), or T2 or both (interval) and persistence of psychotic experiences (that is, presence of psychotic experiences at both T2 (lifetime) and T3 (interval))
None
Fig 2 Response rates and reasons for loss to follow-up
None
Fig 3 Cannabis-psychosis persistence model. Person A has normal developmental expression of subthreshold psychotic experiences that are mild and transient. Person B has similar expression but longer persistence because of additional environmental exposure (here cannabis). Person C has prolonged persistence and subsequent transition to clinical psychotic disorder because of repeated environmental exposure—that is, repeated cannabis use
See this image and copyright information in PMC

Comment in

References

    1. Wittchen HU, Behrendt S, Hofler M, Perkonigg A, Rehm J, Lieb R, et al. A typology of cannabis-related problems among individuals with repeated illegal drug use in the first three decades of life: evidence for heterogeneity and different treatment needs. Drug Alcohol Depend 2009;102:151-7. - PubMed
    1. Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 2008;103:439-51. - PubMed
    1. Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007;88(suppl 1):60-70S. - PubMed
    1. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28. - PubMed
    1. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319-27. - PubMed

Publication types